Welcome Anonymous User  
You are here > Home > View Story

Shenfuqiangxin Capsule inhibits apoptosis through mitogen-activated protein kinase signal pathway in rats with cardio-renal syndrome induced by infrarenal aortic-clamping

Author: Wang L, Wang Z, Yuan L, Hao D, L N, Li X
Page: 80

Brief:
OBJECTIVE: To investigate the effect of Shenfuqiangxin capsule and the underlying mechanism on cardio-renal syndrome (CRS) in rats induced by infrarenal aortic-clamping after renal ischaemia. METHODS: Male Wistar rats underwent infrarenal aortic-clamping after renal ischaemia or sham operation. The surviving CRS rats were divided randomly into three groups: CRS group (CRS + 10 mLkg-1d-1 pure water by gavage), SFQX group (CRS + 13.2 g crude drugkg-1d-1 Shenfuqiangxin by gavage), and handle region peptide (HRP) group (CRS + 10 mg/kg HRP by vein). Sham operation rats were given 10 mLkg-1d-1 pure water. Treatments were given 8 weeks after surgery, which lasted for 4 weeks. The rats were detected for heart structure and function by transthoracic echocardiography. PPR mRNA was detected by Reverse Transcription Polymerase Chain Reaction (RT-PCR). To determine whether the mitogen-activated protein kinase (MAPK) signal pathway is included in the heart and kidney protective function of Shenfuqiangxin capsule, MAPK related proteins such as posophorylated C-Jun amino terminal kinase (p-JNK), posophorylated extracellular signal-regulated kinase (p-ERK1/2), posophorylated p38 (p-p38) were examined by Western Blot.Apoptosis in heart and kidney tissues were detected by dUTP Nick End Labeling staining. RESULTS: Shenfuqiangxin capsule alleviated myocardial apoptosis and inhibited PRR mRNA expression and p-JNK, p-ERK1/2, p-p38 proteins expression in CRS rats. CONCLUSION: All the results suggest that Shenfuqiangxin capsule improves the injured heart and kidney function maybe through inhibition of MAPK response pathway.

Download:
Full Text Download. [306]

ScholarOne Manuscripts Log In

User ID:

Password:


Forgot ScholarOne password?

Enter your e-mail address to receive an
e-mail with your ScholarOne account information.

Current Volume